Trial intelligence / Profile preview

CROSSING: Tezepelumab in Eosinophilic Esophagitis

2023-504277-20-00Phase 3Authorised

Sponsor: AstraZeneca
Start: Jan 2023
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 22

Overview

Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Tezspire with Placebo (2 arms). Primary endpoints: Histologic response at Week 24 and Change in DSQ score at Week 24. Planned start Jan 2023; status: authorised.

Drugs

tezepelumab

Conditions

eosinophilic esophagitis (EoE)

Beyond the preview

Go deeper on 2023-504277-20-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-504277-20-00.